Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Dicks Sporting Goods Inc (DKS) Price & Performance

Cytokinetics IncTrade
Dicks Sporting Goods IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Dicks Sporting Goods Inc — how do they compare? Cytokinetics Inc trades at $76.44 (market cap $10.63B), while Dicks Sporting Goods Inc trades at $203.61 (market cap $18.35B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKDKS
Market Cap
$10.63B$18.35B
Sector
TechnologyConsumer Cyclical
52-Week High
$87.26$239.17
52-Week Low
$34.31$187.78
Enterprise Value
$10.74B$25.14B
Dividend Yield
2.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Dicks Sporting Goods Inc

Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.

The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS